Q3 EPS Forecast for Abbott Laboratories Raised by Analyst

Abbott Laboratories (NYSE:ABT - Free Report) - Investment analysts at William Blair upped their Q3 2025 earnings per share estimates for shares of Abbott Laboratories in a research note issued on Thursday, April 17th. William Blair analyst M. Andrew now anticipates that the healthcare product maker will post earnings per share of $1.33 for the quarter, up from their previous estimate of $1.32. The consensus estimate for Abbott Laboratories' current full-year earnings is $5.14 per share. William Blair also issued estimates for Abbott Laboratories' Q1 2026 earnings at $1.17 EPS, Q2 2026 earnings at $1.38 EPS, Q4 2026 earnings at $1.63 EPS and FY2026 earnings at $5.67 EPS.

Several other research firms also recently weighed in on ABT. Morgan Stanley upped their price target on Abbott Laboratories from $117.00 to $127.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 17th. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research note on Thursday, April 17th. Evercore ISI upped their price objective on Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research report on Thursday, January 2nd. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research note on Tuesday, January 28th. Finally, Royal Bank of Canada boosted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of "Moderate Buy" and an average target price of $142.59.

Abbott Laboratories Stock Down 1.7 %

Shares of ABT stock traded down $2.28 during mid-day trading on Friday, reaching $129.45. 5,262,468 shares of the company's stock traded hands, compared to its average volume of 6,027,925. The company has a market cap of $224.51 billion, a P/E ratio of 16.92, a P/E/G ratio of 2.52 and a beta of 0.80. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The company's 50-day moving average price is $130.61 and its 200-day moving average price is $122.15.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion.

Hedge Funds Weigh In On Abbott Laboratories

A number of large investors have recently bought and sold shares of the business. Redwood Park Advisors LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Noble Wealth Management PBC purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. NewSquare Capital LLC boosted its holdings in Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock valued at $27,000 after purchasing an additional 105 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $28,000. Finally, Rialto Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Insider Activity

In other news, EVP Andrea F. Wainer sold 949 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $131,123.33. Following the completion of the transaction, the executive vice president now directly owns 74,381 shares in the company, valued at $10,277,222.77. This trade represents a 1.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares of the company's stock, valued at $16,152,064.50. This represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 116,449 shares of company stock worth $15,463,316. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.82%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio is 30.61%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.